Results 241 to 250 of about 63,047 (307)

Association between medical comorbidities at diagnosis and paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma outcomes: protocol for a systematic review. [PDF]

BMJ Open
Amankwah EK, Mosha M, Dean J, Mayer J.
europepmc   +1 more source

One‐year follow‐up after fractionated ultra‐high‐dose‐rate FLASH radiotherapy in patient with extramammary Paget disease of the scrotum

Precision Radiation Oncology, Volume 10, Issue 2, Page 120-126, June 2026.
An elderly male patient with extramammary Paget disease of the scrotum and multiple metastases was treated with fractionated FLASH‐RT (40 Gy in 5 fractions) in the scrotal lesion. Abstract Objective Ultrahigh‐dose‐rate radiotherapy (FLASH‐RT) has been shown to reduce radiation‐induced normal tissue injury in preclinical studies.
Hui Luo, Chengliang Yang, Ronghu Mao, Leijie Ma, Hongchang Lei, Peng Chen, Yanping Zhang, Meng Xu, Chao Wang, Yiwu Wang, Mingxia Wu, Chanjun Sun, Han Liu, Hui Liu, Hong Ge   +14 more
wiley   +1 more source

Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase. [PDF]

Clin Pharmacol Ther
Jarugula P, Ajavon-Hartmann T, Obianom O, Ludwig E, Crevar C, Marchisin D, Wang Z, Chen W, He B, Mitchell LG, Rodriguez V, Lew G, Perera V, Murthy B, Merali S.   +14 more
europepmc   +1 more source

Aosta Valley animal cancer registry: A collaborative initiative for monitoring cancer burden in animals

Veterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Animal cancer registry data are important for monitoring animal health, for prevention and research in veterinary medicine, and for comparative oncology. Since people and animals share the same environment and are exposed to many common risk factors, cancer patterns in animals may have a sentinel function for human health.
Claudio Trentin, Giulio Barigelletti, Caterina Abate, Giovanna Michela Villa, Emilio Bazzocchi, Lorenzo Domenis, Silvia Vuillermoz, Magda Giulia Santini, Barbara Avuzzi, Alessandro Borgini, Giovanna Tagliabue   +10 more
wiley   +1 more source

Nelarabine for T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma. [PDF]

Aust Prescr
europepmc   +1 more source

Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma. [PDF]

Ann Hematol
Meng M, Feng X, Zhang Y, Gao Y, Han L, Li Z, Zhang X, Zhang M.   +7 more
europepmc   +1 more source

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review. [PDF]

Discov Oncol
Zhou M, Yang Y, Zhang X, Jiao Y, Guo Z.
europepmc   +1 more source

Bispecific Ligand‐Based EphB4 CAR‐T Cells Generated Using Ephrin‐B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma

Cancer Science, Volume 117, Issue 6, Page 1724-1735, June 2026.
EphB4 and EphA2 positivity in lung adenocarcinoma samples was high. Ligand‐based EphB4 CAR‐T cells exhibit bispecificity, targeting both EphB4 and EphA2. EphB4 CAR‐T cells exert significant antitumor effects against lung adenocarcinoma. ABSTRACT Chimeric antigen receptor (CAR)‐T cells generated using ephrin‐B2, the natural ligand for ephrin type‐B ...
Hirotaka Kumeda, Koichi Hirabayashi, Shuji Mishima, Kotaro Morita, Yu Furui, Marina Fujioka, Tomoyuki Nakajima, Miyuki Tanaka, Yoshinori Sato, Takeshi Uehara, Shigeki Yagyu, Kimihiro Shimizu, Yozo Nakazawa   +12 more
wiley   +1 more source

Synchronous childhood T-lymphoblastic lymphoma and B-cell precursor acute lymphoblastic leukemia associated with constitutional MMR deficiency syndrome -a case report. [PDF]

Front Oncol
Bulsa J, Pastorczak AK, Taha J, Mlynarski W, Sędek Ł, Szczepanski T.   +5 more
europepmc   +1 more source

Tumor‐Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Despite advances in novel therapeutic modalities, such as molecularly targeted agents and immunotherapies, the probability of success in Phase III oncology trials remains low. This study quantitatively characterized success probabilities of Phase III trials in oncology drug development and evaluated the factors associated with trial success ...
Keiko Yamamoto, Aya Iwase, Hideki Maeda
wiley   +1 more source